Cheng Chun-Han, Hao Wen-Rui, Cheng Tzu-Hurng
Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan.
Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan.
World J Gastroenterol. 2025 Jan 7;31(1):100250. doi: 10.3748/wjg.v31.i1.100250.
This article reviews the study, "Fanlian huazhuo formula alleviates high-fat-diet-induced nonalcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway" published in the . The study explores the therapeutic potential of Fanlian Huazhuo formula (FLHZF) in treating metabolic-associated steatotic liver disease (MASLD), demonstrating that FLHZF reduces lipid accumulation, oxidative stress, and liver injury in MASLD models by modulating key signaling pathways involved in lipid metabolism and autophagy. This editorial emphasizes the potential of FLHZF as a treatment for MASLD and calls for further research to verify its clinical efficacy.
本文回顾了发表于……的研究“矾连化浊方通过调节自噬和脂质合成信号通路减轻高脂饮食诱导的非酒精性脂肪性肝病”。该研究探讨了矾连化浊方(FLHZF)治疗代谢相关脂肪性肝病(MASLD)的潜在疗效,表明矾连化浊方通过调节脂质代谢和自噬相关的关键信号通路,减少了MASLD模型中的脂质积累、氧化应激和肝损伤。这篇社论强调了矾连化浊方治疗MASLD的潜力,并呼吁进一步研究以验证其临床疗效。